Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR012 phase II study of NGR-hTNF plus doxorubicin in advanced or metastatic ovarian cancer
2007-000004-33Phase 2Completed
- Sponsor
- MolMed
- Start
- Apr 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGR-TNF and doxorubicin in ovarian cancer, sponsored by MolMed. Primary endpoint: Objective response rate. Started Apr 2007; status: completed.
02
Drugs
NGR-TNFdoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2007-000004-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000004-33.